| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
834 |
700 |
$2K |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
8,039 |
4,452 |
$2K |
| 80053 |
Comprehensive metabolic panel |
4,873 |
3,453 |
$2K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,415 |
3,444 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,678 |
2,097 |
$2K |
| 80061 |
Lipid panel |
1,571 |
1,286 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,584 |
1,273 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,807 |
1,371 |
$1K |
| 85027 |
|
2,977 |
2,032 |
$896.87 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
55 |
37 |
$732.40 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
160 |
111 |
$618.26 |
| 80164 |
|
555 |
431 |
$489.28 |
| 82607 |
|
597 |
505 |
$417.21 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
84 |
63 |
$401.01 |
| 87077 |
|
697 |
541 |
$341.99 |
| 87186 |
|
559 |
465 |
$331.63 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,063 |
784 |
$320.28 |
| 80177 |
|
218 |
172 |
$251.80 |
| 82140 |
|
130 |
89 |
$220.40 |
| 83880 |
|
246 |
174 |
$215.13 |
| G0471 |
Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) |
5,823 |
3,614 |
$184.03 |
| 83735 |
|
425 |
349 |
$181.68 |
| 81001 |
|
1,348 |
992 |
$167.69 |
| 80076 |
|
185 |
145 |
$156.22 |
| 84439 |
|
341 |
287 |
$148.91 |
| 83550 |
|
205 |
165 |
$128.12 |
| 83540 |
|
285 |
224 |
$118.99 |
| 82746 |
|
264 |
215 |
$116.40 |
| 85610 |
|
951 |
262 |
$106.25 |
| 82728 |
|
124 |
108 |
$73.80 |
| 36415 |
Collection of venous blood by venipuncture |
4,657 |
1,738 |
$37.35 |
| 86140 |
|
47 |
38 |
$20.74 |
| 84132 |
|
43 |
34 |
$14.28 |
| 84550 |
|
26 |
24 |
$13.56 |
| 80069 |
|
18 |
14 |
$13.02 |
| 84134 |
|
28 |
26 |
$10.94 |
| 80185 |
|
16 |
12 |
$9.94 |
| 83719 |
|
249 |
184 |
$0.00 |
| 87070 |
|
14 |
12 |
$0.00 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,538 |
732 |
$0.00 |
| 51701 |
|
43 |
30 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
21 |
14 |
$0.00 |